Fluidra announced that its Board of Directors has appointed Juan Graham as Chief Financial Officer. Graham will join the company and Fluidra?s Executive Committee on 1 June 2026, working closely with Xavier Tintoré over the coming months to ensure a smooth and well-coordinated transition. Xavier will step down as Chief Financial Officer on 1 August 2026 and will continue supporting the company until the end of the year as part of the transition.

The appointment follows a planned and orderly succession process linked to Xavier Tintoré?s decision to begin a new professional and personal chapter after 16 years as Fluidra?s CFO. Juan Graham brings more than 25 years of international experience in senior finance roles, combining strong functional expertise with hands-on operational leadership. He spent nearly two decades at Johnson & Johnson, where he held senior leadership positions across consumer health, supply chain operations, treasury, mergers and acquisitions, and global finance.

His experience includes leading finance organizations of significant scale and complexity, including supporting a business with more than $14 billion in annual revenue. Most recently, Graham served as CFO of U.S.-listed companies including FibroGen and Perspective Therapeutics, where he led finance, investor relations, IT and strategic planning functions through periods of transformation and growth. Tintoré has been a key figure in Fluidra?s transformation over the past 16 years, playing a central role not only in the company?s financial leadership, but also across strategy, investor relations, integration and transformation initiatives and several corporate functions.

He was instrumental through some of the company?s most important milestones, including the merger with Zodiac, Fluidra?s inclusion in the IBEX 35, the company?s international expansion and numerous strategic acquisitions.